CDC Adds Two Quantabio RT-qPCR ToughMix Kits to COVID-19 Diagnostic Testing Protocol
qScript XLT 1-Step RT-qPCR ToughMix and UltraPlex 1-Step ToughMix granted Emergency Use Authorization
Quantabio’s qScript XLT 1-Step RT-qPCR ToughMix and UltraPlex 1-Step ToughMix have been granted Emergency Use Authorization (EUA) and added to the Centers for Disease Control and Prevention (CDC) protocol for the 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel. Part of Quantabio’s ToughMix family, these two robust, one-step RT-qPCR kits are ideal for the quantification of RNA viruses because they deliver maximum efficiency, sensitivity and specificity in minimal reaction volumes and accelerated thermal cycling rates.
RT-qPCR ToughMix Solutions
TheUltraPlex 1-Step ToughMixis a ready-to-use, 4X concentrated master mix for 1-step reverse transcription and RT-qPCR of RNA templates using probe-based detection methods.
TheqScript XLT 1-Step RT-qPCR ToughMixis a ready-to-use master mix for RT-qPCR of RNA templates using hybridization probe detection chemistries such as TaqMan®5′-hydrolysis probes.
Quantabio has built a strong track record in developing reliable molecular biology reagents that offer superior performance in terms of sensitivity, reproducibility, and specificity. Our products have been widely adopted by hundreds of public health and clinical testing labs around the world. They are also used in the protocols for the CDC’s influenza and WHO Polio diagnostic assays.